We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
-20.15%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$609M
AUM Growth
-$187M
Cap. Flow
+$3.48M
Cap. Flow %
0.57%
Top 10 Hldgs %
91.9%
Holding
14
New
1
Increased
–
Reduced
4
Closed
–

Top Buys

Rank Stock Value
1
HOWL icon
Werewolf Therapeutics
HOWL
+$32.7M

Top Sells

Rank Stock Value
1
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$13.4M
2
RPTX
Repare Therapeutics
RPTX
+$12.9M
3
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$2.55M
4
ITOS
iTeos Therapeutics
ITOS
+$404K

Sector Composition

Rank Sector Weight
1 Healthcare 95.25%
2 Miscellaneous 4.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEM icon
1
Cullinan Oncology
CGEM
$1.4B
$204M 33.48%
7,913,887
– –
ITOS
2
DELISTED
iTeos Therapeutics
ITOS
$60M 9.85%
2,338,581
-16,976
-0.7% -$404K
TCRR
3
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$55.3M 9.09%
3,370,982
– –
RPTX
4
DELISTED
Repare Therapeutics
RPTX
$52.3M 8.59%
1,676,087
-393,662
-19% -$12.9M
HARP
5
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$44.3M 7.28%
319,671
-70,171
-18% -$13.4M
HOWL icon
6
Werewolf Therapeutics
HOWL
$45.8M
$41.6M 6.84%
+2,388,011
New +$32.7M
ONCR
7
DELISTED
Oncorus, Inc.
ONCR
$32.8M 5.39%
2,377,031
– –
TPTX
8
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$21M 3.45%
269,186
– –
EPZM
9
DELISTED
Epizyme, Inc
EPZM
$19.4M 3.18%
2,331,534
– –
GTHX
10
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$17.8M 2.93%
812,794
-115,000
-12% -$2.55M
MRUS
11
DELISTED
Merus
MRUS
$14.8M 2.43%
700,879
– –
YMAB
12
DELISTED
Y-mAbs Therapeutics
YMAB
$11.4M 1.87%
337,291
– –
ADCT icon
13
ADC Therapeutics
ADCT
$146M
$5.31M 0.87%
218,027
– –

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q2 2021 Portfolio in Review

As of Q2 2021, MPM BioImpact held 14 positions worth $609M, down 24% from $796M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

MPM BioImpact's Q2 2021 filing shows 1 new and 4 reduced positions. Its largest new stake was Werewolf Therapeutics: 2,388,011 shares worth $41.6M. The largest sale was Harpoon Therapeutics, Inc. Common Stock, an estimated $13.4M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Miscellaneous.

  • MPM BioImpact's largest Q2 2021 buy was Werewolf Therapeutics: 2,388,011 shares worth $41.6M.
  • MPM BioImpact's biggest Q2 2021 reduction was Harpoon Therapeutics, Inc. Common Stock, cutting an estimated $13.4M.
  • MPM BioImpact's ten largest holdings make up 92% of its $609M portfolio in Q2 2021.
  • MPM BioImpact opened 1 new position and closed 0 in Q2 2021.
  • MPM BioImpact's portfolio value fell 24% quarter-over-quarter to $609M.

Based on MPM BioImpact's 13F filing for Q2 2021, filed 13 Aug 2021.